What is the brand name for adalimumab?

The available brand can depend on the local market and dispensing service. Adalimumab is the active medicine name, so it is the clearest term to use when checking whether differently branded products contain the same biologic medicine.

Adalimumab is a biologic that modifies a specific inflammatory signal called tumour necrosis factor. A biosimilar is developed to be highly similar to an existing biologic, with no clinically meaningful differences expected in how it works, but its brand name, pen design, syringe, inactive ingredients, and packaging may differ. A brand change therefore does not necessarily mean that the prescribed active medicine has changed.

Read the dispensing label and carton for the words adalimumab, the prescribed strength, and the correct dosing schedule. If a refill looks unfamiliar, compare the device and storage directions with the training you received. A pharmacist or prescribing team can confirm whether the new package is a planned biosimilar substitution and demonstrate a different pen or syringe.

Keep the product in its recommended storage conditions and follow its own instructions for preparation, injection, and disposal. Never combine doses from different devices to improvise a prescribed dose.

Contact the treating team promptly for fever, a persistent cough, painful urination, an infected wound, or another possible infection, and seek urgent help for trouble breathing, facial swelling, or a severe allergic reaction. Obtain advice before injecting if the seal is damaged, the liquid looks abnormal for that product, the device malfunctioned, or you cannot verify what was dispensed.

Confirm the active medicine and brand you will receive, whether future refills may look different, and who will provide device training. Ask how to handle a late or missed dose, what infection screening and monitoring apply to you, which vaccines should be discussed, and whom to contact if your symptoms change after a switch.